secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104592
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk Q2 net loss $52.6M; cash $177.2M, runway to 2028
----------------------------------------------------------

- Net loss of $52.6M vs $14.6M Q2 2024; includes $38M upfront payment under Wuxi ADC deal.
- Cash, equivalents & short-term investments $177.2M at June 30, 2025 (vs $47.2M Dec 31, 2024).
- IND filings on track: HWK-007 and HWK-016 by year-end 2025; HWK-206 by mid-2026.
- Cash anticipated to fund operations into 2028, enabling initial clinical data readouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000095017025104592/0000950170-25-104592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000095017025104592/whwk-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer